Navigation Links
AMT to Release Full Year 2008 Results on February 24, 2009
Date:2/18/2009

AMSTERDAM, The Netherlands, February 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it will release its financial results for the full year 2008 on Tuesday, February 24, 2009 at 7:00 am Central European Time (CET). To discuss these results, the Company will conduct a conference call that day at 3 p.m. CET.

The dial-in number for the Netherlands is 0800-949-4166 (toll free). The number for Germany is 0800-000-22-63 (toll free). For the UK the number is +44-207-107-0611 and for the rest of Europe: +41-91-610-5600. The number for the USA is +1-866-291-4166 (toll free). To listen to the conference call live via the internet, visit the investor relations portion of the AMT website at http://www.amtbiopharma.com. Please go to the website fifteen minutes prior to the call to register, download and install the necessary audio software.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV GMP production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of (rare) diseases that are caused by one faulty gene. AMT currently has a product pipeline with nine products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans,"
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. New Edition of Definitive Resource in Tissue Engineering Released Today
2. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
3. Instant JChem 2.0 Released: Instant JChem Personal Free for All Users
4. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
5. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
6. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
7. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
8. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
9. Dynatronics to Release Fourth Quarter and Year-end Results Friday, September 14, 2007; Conference Call set for 1:00 p.m. ET
10. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
11. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Nov.25/PRNewswire/--BiotechfirmReplikinsLtd.,which...emicthroughtheprediction,outbreak,andprogressofthe...lanalysisofthevirus.Thenewdatashowsthatthelethalit...3.7(s.d.4.5)duringthevirus,scurrentoutbreakinthesp...(s.d.0.1).TheH1N1virus,infectivitycount,however,re...
(Date:11/25/2009)...,Nov.25/PRNewswire/--Reportlinker.comannouncesthat... ,, BrazilBioethanolMarketAnalysisandForecasts...3/Brazil-Bioethanol-Market-Analysis-and-Forecasts-...andForecaststo2013 ,, Summary ,, Thereport...ethanolmarketandtheBrazilbioethanolmarketinparticu...
(Date:11/24/2009)... The New York investment bank KTA Capita...s agreed an AU$6.7 mil convertible note private pl...ivate placement was arranged by KTA Capital as Neu... New York (PRWEB) November 23... KTA Capital, LLC ("KTA Capital") has an...
(Date:11/24/2009)... Health care employment grew by 29,000...ne to show consistent growth during the U.S. reces...ain in trouble, and health systems are coming clos...stead of just administrators. , ...ployment continued growing in October despite the ...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
... Feb. 24 /PRNewswire-FirstCall/ - Angiotech Pharma...bal specialty pharmaceutical and medical device co... quarter and year end conference call. The call wi...day, March 5, 2009. , , , Dial information for...d, and is as follows:, North America (toll-f...
...s Effect on Reduction of Exacerbations is the Attr... Decisions, According to a New Report from Decisio... Resources, one of the world,s leading research an... issues, finds that Novartis/Schering-Plough,s ind...bicort as Decision Resources, proprietary clinical...
... Highlighted by Cinryze(TM) [C1 Inhibitor (human)]...roPharma Incorporated (Nasdaq: VPHM ) reported t...and year ended December 31, 2008. , , Key events ...: , , , Closed on acquisition of Lev Pha...Initiated commercial launch of Cinryze for routine...
Other Biology Technology:Novartis/Schering-Plough's Drug Will Replace AstraZeneca's Symbicort as Decision Resources' Clinical Gold Standard by 2012 for the Treatment of Asthma 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 12
(Date:11/23/2009)...ommunity-associated strain of the deadly superbug ...t common antibioticsposes a far greater health thr...to hospitals, according to a study in the December... new threat is easily picked up in fitness centers...ed the overall burden of MRSA within hospitals, th...
(Date:11/23/2009)...ldlife Conservation Society says that western lowl...ic of Congopart of the "mother lode" of more than ...increasingly threatened by growing humans activity...n of the swamp forests adjacent to the southwest b...veys confirmed that high densities of the great ap...
(Date:11/23/2009)...w study provides "incontrovertible evidence" that ...of Sumatra about 73,000 years ago deforested much ...ter, researchers report. , The volcano ejected a...tmosphere, leaving a crater (now the world,s large...35 kilometers wide. Ash from the event has been fo...
Breaking Biology News(10 mins):New study finds MRSA on the rise in hospital outpatients 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Free LASIK Surgery Webinar 62029 1Free LASIK Surgery Webinar 62029 2Free LASIK Surgery Webinar 62029 3Free LASIK Surgery Webinar 62029 4TeamStaff Announces Transfer to Nasdaq Capital Market 62025 1TeamStaff Announces Transfer to Nasdaq Capital Market 62025 2TeamStaff Announces Transfer to Nasdaq Capital Market 62025 3Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 1Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 2
...erimental procedure that dramatically strengthens ...ould offer new hope to sufferers of muscle-wasting... according to researchers from the University of N...e has been successfully used to regrow muscles in ...ue-based illnesses in humans such as in the liver,...
... professionals send genes and healthy cells on the...or example, repair tissue damage to arteries. But ...tities? Scientists of the PTB have developed a hig...ciency of this therapy can be investigated: Small ...ed gene or on the planted cell can with the aid of...
...g to shed new light on HIV,s ability to survive in...e of Allergy and Infectious Diseases at the NIH ha...DS research team at the New York University Colleg... of HIV replication that involves cooperation betw..., an Assistant Professor of Basic Science and Cran...
Other Biology News:Stem cell breakthrough gives new hope to sufferers of muscle-wasting diseases 2NYU College of Dentistry awarded $1.9 million NIH grant for HIV research 2
...ustom peptide synthesis with a wide variety of pur...our research needs. Purity: IG(>50%), >70%, >80... to 120 residues Modifications: Biotin, Fluores... D-amino acids, MAPs, KLH/BSA conjugation, and muc...
...o 10 represents a major advance in liquid dispensi...large robotic liquid handlers into the realm of th...lumes ranging from 10mL to 2mL per well, the micro...enchtop dispensers. ,Features: , Never nee...
Human CALCA EIA (Enzyme immunoassay) Kit, Host: Rabbit ; Extraction-free from BACHEM
PerkinElmer Spectrum Beer's Law QUANT Quantitative Software, CD from PerkinElmer
Biology Products: